John Vavricka - 31 Jan 2026 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)

Role
Chief Commercial Officer
Signature
/s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka
Issuer symbol
AVIR
Transactions as of
31 Jan 2026
Net transactions value
-$49,057
Form type
4
Filing time
03 Feb 2026, 19:47:27 UTC
Previous filing
04 Feb 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Vavricka John Chief Commercial Officer 225 FRANKLIN STREET, SUITE 2100, BOSTON /s/ Andrea Corcoran, as Attorney-in-Fact for John Vavricka 03 Feb 2026 0001829630

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AVIR Common Stock Options Exercise +42,083 +81% 94,164 31 Jan 2026 Direct F1
transaction AVIR Common Stock Tax liability $49,057 -11,570 -12% $4.24 82,594 31 Jan 2026 Direct
holding AVIR Common Stock 82,508 31 Jan 2026 Held by John Vavricka as the Trustee of the John F. Vavricka Deed of Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AVIR Restricted Stock Units Options Exercise $0 -33,333 -100% $0.000000 0 31 Jan 2026 Common Stock 33,333 Direct F1, F2
transaction AVIR Restricted Stock Units Options Exercise $0 -8,750 -100% $0.000000 0 31 Jan 2026 Common Stock 8,750 Direct F1, F3
transaction AVIR Stock Option (Right to Buy) Award $0 +119,520 $0.000000 119,520 31 Jan 2026 Common Stock 119,520 $4.24 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2 The original grant of 100,000 RSUs vested in three (3) equal annual installments on the first three anniversaries of January 31, 2023 such that the RSUs were fully vested as of January 31, 2026.
F3 Reflects RSUs following the satisfaction of performance criteria of previously granted performance restricted stock units that vested on January 31, 2026.
F4 The option vests and becomes exercisable in forty-eight (48) equal monthly installments following January 31, 2026 such that the option is fully vested on January 31, 2030.